Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Immunology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int Immunopharmacol. 2021 Aug;97:107679. doi: 10.1016/j.intimp.2021.107679. Epub 2021 Apr 15.
The calamity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), COVID-19, is still a global human tragedy. To date, no specific antiviral drug or therapy has been able to break the widespread of SARS-CoV2. It has been generally believed that stimulating protective immunity via universal vaccination is the individual strategy to manage this pandemic. Achieving an effective COVID-19 vaccine requires attention to the immunological and non-immunological standpoints mentioned in this article. Here, we try to introduce the considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development. Also, the principal features of the preclinical and clinical studies of pioneering COVID-19 vaccine candidates were pointed out by reviewing the available information. Finally, we discuss the key challenges in the successful design of the COVID-19 vaccine and address the most fundamental strengths and weaknesses of common vaccine platforms.
新型严重急性呼吸综合征冠状病毒 2(SARS-CoV2),即 COVID-19 的灾难仍然是一场全球性的人类悲剧。迄今为止,尚无能够阻止 SARS-CoV2 广泛传播的特定抗病毒药物或疗法。人们普遍认为,通过普遍接种疫苗来刺激保护性免疫是管理这种大流行的个体策略。要实现有效的 COVID-19 疫苗,需要关注本文所述的免疫学和非免疫学观点。在这里,我们试图介绍相当多的免疫学方面、潜在的抗原靶点、合适的佐剂以及 COVID-19 疫苗开发各个阶段的要点。此外,通过回顾现有信息,指出了开创性 COVID-19 疫苗候选物的临床前和临床研究的主要特征。最后,我们讨论了成功设计 COVID-19 疫苗的关键挑战,并讨论了常见疫苗平台的最基本优势和劣势。